Sage claims an­oth­er big win on a small study, this time for post­par­tum de­pres­sion

Shares of Sage Ther­a­peu­tics $SAGE rock­et­ed up 38% this morn­ing af­ter the Cam­bridge, MA-based biotech post­ed re­mark­able da­ta from a small study of its lead drug for post­par­tum de­pres­sion.

So far, Sage has con­cen­trat­ed much of its at­ten­tion tout­ing the im­pact of SAGE-547 on rare cas­es of pro­tract­ed seizures called su­per-re­frac­to­ry sta­tus epilep­ti­cus. But CEO Jeff Jonas has al­so been pur­su­ing a the­o­ry that the drug can have an im­pact on mood dis­or­ders like de­pres­sion, a tough field that has seen a se­ries of painful prat­falls by de­vel­op­ers over the years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.